Aligos Therapeutics, Inc. (ALGS) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -75.96M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-75.96M | (m) |
| 2026-03-31 | (m) | $-90.32M | (m) |
| 2025-12-31 | (m) | $-24.19M | (m) |
| 2025-09-30 | (m) | $-86.46M | (m) |
| 2025-06-30 | (m) | $-74.18M | (m) |
| 2025-03-31 | (m) | $-53.26M | (m) |
| 2024-12-31 | (m) | $-131.21M | (m) |
| 2024-09-30 | (m) | $-76.95M | (m) |
| 2024-06-30 | (m) | $-75.73M | (m) |
| 2024-03-31 | (m) | $-99.59M | (m) |
| 2023-12-31 | (m) | $-87.68M | (m) |
| 2023-09-30 | (m) | $-81.67M | (m) |
| 2023-06-30 | (m) | $-82.25M | (m) |
| 2023-03-31 | (m) | $-83.39M | (m) |
| 2022-12-31 | (m) | $-96.05M | (m) |
| 2022-09-30 | (m) | $-111.87M | (m) |
| 2022-06-30 | (m) | $-126.38M | (m) |
| 2022-03-31 | (m) | $-136.27M | (m) |
| 2021-12-31 | (m) | $-128.33M | (m) |
| 2021-09-30 | (m) | $-125.04M | (m) |
| 2021-06-30 | (m) | $-125.21M | (m) |
| 2021-03-31 | (m) | $-116.19M | (m) |
| 2020-12-31 | (m) | $-108.54M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $-52.26M | (m) |
| 2019-09-30 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |